임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
24건 표시
- 1상모집 중단 (진행 중)· Small Cell Lung CarcinomaA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
리드: BMS
- 1상모집 중단 (진행 중)· Advanced Solid TumorsA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
리드: BMS
- 1상모집 중단 (진행 중)· DLBCL - Diffuse Large B Cell LymphomaLow Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
협력: BMS
- 1상모집 중단 (진행 중)· Classical Hodgkin LymphomaAutologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
협력: BMS
- 1상모집 중단 (진행 중)· Multiple MyelomaCPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
협력: BMS
- 1상모집 중단 (진행 중)· Hepatocellular CarcinomaFeasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
협력: BMS
- 1상모집 중단 (진행 중)· Advanced Solid TumorStudy of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
협력: BMS
- 1상모집 중단 (진행 중)· Pancreatic Ductal AdenocarcinomaA Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
협력: BMS
- 1상모집 중단 (진행 중)· Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
협력: BMS
- 1상모집 중단 (진행 중)· Recurrent GlioblastomaIL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
협력: BMS
- 1상모집 중단 (진행 중)· Malignant Pleural MesotheliomaA Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
협력: BMS
- 1상모집 중단 (진행 중)· OsteosarcomaNivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
협력: BMS
- 1상모집 중단 (진행 중)· Pathologic Stage IIIB Cutaneous Melanoma AJCC v8VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
협력: BMS
- 1상모집 중단 (진행 중)· Follicular LymphomaNivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
협력: BMS
- 1상모집 중단 (진행 중)· Gastric CancerNivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
협력: BMS
- 1상모집 중단 (진행 중)· Chronic Lymphocytic Leukemia (CLL)A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
협력: BMS
- 1상모집 중단 (진행 중)· Multiple MyelomaBCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
협력: BMS
- 1상모집 중단 (진행 중)· Squamous Cell Carcinoma of the Head and NeckIpilimumab for Head and Neck Cancer Patients
협력: BMS
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.